Patents by Inventor Daniel J. Sexton

Daniel J. Sexton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220291232
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Application
    Filed: December 20, 2021
    Publication date: September 15, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • Patent number: 11401346
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: August 2, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Publication number: 20220223299
    Abstract: Aspects of the present application provide for methods and apparatuses for modeling, simulating, and treating hereditary angioedema (HAE). According to some aspects, a quantitative systems pharmacology (QSP) model is provided for simulating the efficacy of drug intervention under context of HAE pathophysiology. The QSP model may comprise a plurality of individual models including one or more PK models and/or one or more PD models for simulating drug exposure, target engagements and acute attack rate in HAE patients. A virtual patient population representing a plurality of virtual patients may be developed and input into the QSP model for executing a virtual clinical trial. In some embodiments, the QSP model may be used evaluate a response of the contact system and/or an effectiveness of a therapeutic intervention for treating HAE.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 14, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Rangaraj Narayanan, Hoa Q. Nguyen, Daniel J. Sexton
  • Publication number: 20220213949
    Abstract: A traction device including a ring member, a carrier, and a sun member and an electric motor, wherein the electric motor is coupled to at least one of the ring member, the carrier, and the sun member.
    Type: Application
    Filed: February 18, 2022
    Publication date: July 7, 2022
    Inventors: Jeffrey M. DAVID, Daniel J. DAWE, Charles B. LOHR, III, Gordon M. MCINDOE, Travis J. MILLER, Sebastian J. PETERS, Patrick R. SEXTON
  • Patent number: 11369508
    Abstract: A urine collection device includes a collection member extending from a proximal end to a distal end. The proximal end includes an opening that provides access to an internal cavity of the collection member. The internal cavity includes a first chamber in fluid communication with a second chamber. The urine collection device includes a spacer in the second chamber, a first attachment member extending from a bottom wall of the collection member at the proximal end, a second attachment member extending from a top wall of the collection member at the proximal end, and an outlet for egressing urine from the internal cavity of the collection member. The first attachment member defines an aperture. The collection member is suitable to (i) direct urine from the first chamber to the second chamber and (ii) direct the urine in the second chamber distally toward the outlet.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: June 28, 2022
    Assignee: Sage Products, LLC
    Inventors: Brian J. Ecklund, Kristin M. Sexton, Alex D. Kea, Daniel R. Ulreich
  • Patent number: 11372002
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • Publication number: 20220170936
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Application
    Filed: October 1, 2021
    Publication date: June 2, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Publication number: 20220169749
    Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in preventing hereditary angioedema attack or reducing the rate of hereditary angioedema attack.
    Type: Application
    Filed: October 13, 2021
    Publication date: June 2, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yung Chyung, Burt Adelman, Daniel J. Sexton
  • Patent number: 11340237
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 24, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • Publication number: 20220033521
    Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
    Type: Application
    Filed: June 11, 2021
    Publication date: February 3, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
  • Patent number: 11156612
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Publication number: 20210322972
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Application
    Filed: November 24, 2020
    Publication date: October 21, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette
  • Publication number: 20210309741
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: March 17, 2021
    Publication date: October 7, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • Publication number: 20210285962
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: September 15, 2017
    Publication date: September 16, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • Publication number: 20210270842
    Abstract: The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.
    Type: Application
    Filed: January 5, 2021
    Publication date: September 2, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Janja Cosic
  • Patent number: 11084884
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: August 10, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • Publication number: 20210230299
    Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
    Type: Application
    Filed: December 29, 2020
    Publication date: July 29, 2021
    Applicant: Dyax Corp.
    Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
  • Patent number: 11046785
    Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: June 29, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
  • Patent number: 11014988
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: May 25, 2021
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • Publication number: 20210087293
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Application
    Filed: September 2, 2020
    Publication date: March 25, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp